Mark B. Faries
- Oncology top 0.2%
- Molecular Biology top 2%
- Immunology top 1%
- Epidemiology top 2%
- Cancer Research top 2%
- Co-authors
- Donald L. MortonJohn F. ThompsonBrendan D. CurtiMerrick I. RossCharles M. BalchJohn M. KirkwoodVernon K. SondakRichard A. Scolyer
- Topics
- Cutaneous Melanoma Detection and Management (94 papers)Immunotherapy and Immune Responses (62 papers)CAR-T cell therapy research (48 papers)
- Cited by
- OncologyImmunologyDermatology
- Partner nations
- United StatesAustraliaNetherlands
In The Last Decade
Mark B. Faries
167 papers receiving 7.4k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Oncology 5.9k
- Molecular Biology 2.6k
- Immunology 2.2k
- Epidemiology 1.5k
- Cancer Research 689
Countries citing papers authored by Mark B. Faries
This map shows the geographic impact of Mark B. Faries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark B. Faries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark B. Faries more than expected).
Fields of papers citing papers by Mark B. Faries
This network shows the impact of papers produced by Mark B. Faries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark B. Faries. The network helps show where Mark B. Faries may publish in the future.
Co-authorship network of co-authors of Mark B. Faries
This figure shows the co-authorship network connecting the top 25 collaborators of Mark B. Faries. A scholar is included among the top collaborators of Mark B. Faries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark B. Faries. Mark B. Faries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 10 | |
| 4 | 0 | |
| 5 | 1 | |
| 6 | 50 | |
| 7 | 5 | |
| 8 | 5 | |
| 9 | 2 | |
| 10 | 22 | |
| 11 | 3 | |
| 12 | 113 | |
| 13 | 24 | |
| 14 | 7 | |
| 15 | 35 | |
| 16 | 125 | |
| 17 | 75 | |
| 18 | 114 | |
| 19 | Low lymph flow decreases with age and correlates with non-sentinel node metastases and poor survival in stage III melanoma | 1 |
| 20 | 27 |
About Mark B. Faries
Mark B. Faries is a scholar working on Oncology, Immunology and Biotechnology, having authored 173 papers that have together received 7.5k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (94 papers), Immunotherapy and Immune Responses (62 papers) and CAR-T cell therapy research (48 papers). The work is most often cited by research in Oncology (5.9k citations), Immunology (2.2k citations) and Dermatology (570 citations). Mark B. Faries has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Donald L. Morton, John F. Thompson, Brendan D. Curti, Merrick I. Ross, Charles M. Balch, John M. Kirkwood, Vernon K. Sondak, Richard A. Scolyer, Robert M. Elashoff and Alexander M.M. Eggermont. Their work appears in journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.